Communiqués Cereno Scientific AB

Actions

CRNO B

SE0008241558

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
6,1 ^SEK	-3,17 %		-13,90 %	+33,33 %

09/07	Cereno Scientific obtient de nouveaux brevets pour son médicament candidat contre l'hypertension artérielle	MT
28/06	Premier sujet traité dans le cadre du premier essai de phase I chez l'homme du nouvel inhibiteur d'HDAC Cs014 de Cereno Scientific	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Cereno Scientific Extends Financial Runway by Extending Loan Maturity Date	10/07	AQ
Cereno Scientific reports acquired warrants within the framework of the incentive program resolved at the Annual General Meeting	10/07	AQ
Cereno Scientific expands patent protection for PAH drug candidate CS1:s second and third patent family	09/07	AQ
BioStock: Cereno's CEO comments on progress with CS1 and CS014	08/07	AQ
Cereno Scientific announces final milestone payment to Emeriti Bio for CS014	05/07	AQ
Cereno Scientific's Board of Directors and Executive Management enter into lock-up agreements	02/07	AQ
First subject dosed in Cereno Scientifics first-in-human Phase I trial of novel HDAC inhibitor CS014	28/06	AQ
Cereno Scientific's Phase II trial with CS1 in Pulmonary Arterial Hypertension is closing for recruitment and proceeding to topline	28/06	AQ
Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding CS014 advancing to clinical Phase I	20/06	AQ
BioStock: Cereno's CEO - "CS014 adds potential for cardiovascular disease patients"	20/06	AQ
Cereno Scientific granted approval from, EMA to initiate first-in-human Phase I trial with novel epigenetic HDAC inhibitor, CS014	18/06	AQ
Preclinical data for Cereno Scientific's drug candidate CS585 showing high selectivity for the IP receptor presented at the EHA 2024 Hybrid Congress	16/06	AQ
Cereno Scientific moves to new office space at GoCo Health Innovation City in Gothenburg	10/06	AQ
Cereno Scientific initiates collaboration with the Pulmonary and Vascular Research Institute (PVRI)	03/06	AQ
Cereno Scientific to present preclinical data for drug candidate CS585, a novel IP receptor agonist, at the ESC Congress 2024	30/05	AQ
Cereno Scientific participating at BIO 2024, June 3-6, San Diego	28/05	AQ
Cereno Scientific publishes the interim report for Q1 2024 ( January 1-March 31)	23/05	AQ
Cereno Scientific presents at ABGSC Investor Days, May 23	17/05	AQ
Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress	15/05	AQ
Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025	02/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cereno Scientific AB

Actions

CRNO B

SE0008241558

Communiqués

Filtres